120 related articles for article (PubMed ID: 17599363)
1. Optimal control of treatment in a mathematical model of chronic myelogenous leukemia.
Nanda S; Moore H; Lenhart S
Math Biosci; 2007 Nov; 210(1):143-56. PubMed ID: 17599363
[TBL] [Abstract][Full Text] [Related]
2. Optimal control for resistance and suboptimal response in CML.
Aïnseba B; Benosman C
Math Biosci; 2010 Oct; 227(2):81-93. PubMed ID: 20638391
[TBL] [Abstract][Full Text] [Related]
3. A mathematical model for chronic myelogenous leukemia (CML) and T cell interaction.
Moore H; Li NK
J Theor Biol; 2004 Apr; 227(4):513-23. PubMed ID: 15038986
[TBL] [Abstract][Full Text] [Related]
4. A PDE model for imatinib-treated chronic myelogenous leukemia.
Kim PS; Lee PP; Levy D
Bull Math Biol; 2008 Oct; 70(7):1994-2016. PubMed ID: 18663536
[TBL] [Abstract][Full Text] [Related]
5. Mathematical models of cancer stem cells.
Michor F
J Clin Oncol; 2008 Jun; 26(17):2854-61. PubMed ID: 18539964
[TBL] [Abstract][Full Text] [Related]
6. Modeling imatinib-treated chronic myelogenous leukemia: reducing the complexity of agent-based models.
Kim PS; Lee PP; Levy D
Bull Math Biol; 2008 Apr; 70(3):728-44. PubMed ID: 18060460
[TBL] [Abstract][Full Text] [Related]
7. Differentiation therapy as an effective strategy for the treatment of chronic myelogenous leukemia.
Moosavi MA; Yazdanparast R
Med Hypotheses; 2006; 67(6):1470-1. PubMed ID: 16919395
[No Abstract] [Full Text] [Related]
8. [Circumventing resistance to imatinib therapy in chronic myeloid leukemia].
Minami Y; Naoe T
Gan To Kagaku Ryoho; 2009 Apr; 36(4):544-7. PubMed ID: 19381024
[TBL] [Abstract][Full Text] [Related]
9. Isolated CNS lymphoid blast crisis in a patient with imatinib-resistant chronic myelogenous leukemia: case report and review of the literature.
Aftimos P; Nasr F
Leuk Res; 2009 Nov; 33(11):e178-80. PubMed ID: 19446330
[No Abstract] [Full Text] [Related]
10. Imatinib resistance and progression of CML to blast crisis: somatic hypermutation AIDing the way.
Strout MP; Schatz DG
Cancer Cell; 2009 Sep; 16(3):174-6. PubMed ID: 19732715
[TBL] [Abstract][Full Text] [Related]
11. Promyelocytic blast crisis of chronic myeloid leukemia during imatinib treatment.
Chung HJ; Chi HS; Cho YU; Park CJ; Seo EJ; Kim KH; Lee JH
Ann Clin Lab Sci; 2008; 38(3):283-6. PubMed ID: 18715859
[TBL] [Abstract][Full Text] [Related]
12. A 51-year-old male CML patient with progressive hearing loss, confusion, ataxia, and aphasia during imatinib treatment.
Janssen JJ; Berendse HW; Schuurhuis GJ; Merle PA; Ossenkoppele GJ
Am J Hematol; 2009 Oct; 84(10):679-82. PubMed ID: 19658186
[No Abstract] [Full Text] [Related]
13. Management of conjunctival chemosis secondary to imatinib treatment for chronic myelogenous leukemia.
Jin J; Chen H; Cao L
Leuk Res; 2009 Jun; 33(6):e18-9. PubMed ID: 19108890
[No Abstract] [Full Text] [Related]
14. Development of acute myeloid leukemia associated with Ph-negative clone with inv(3)(q21q26) during imatinib therapy for chronic myeloid leukemia.
Dvorak P; Hruba M; Subrt I
Leuk Res; 2009 Jun; 33(6):860-1. PubMed ID: 18977531
[No Abstract] [Full Text] [Related]
15. Successful imatinib mesylate therapy for acquired von Willebrand syndrome in chronic myelogenous leukemia.
Uchiyama M; Ikeda T
Leuk Res; 2009 Dec; 33(12):1723-4. PubMed ID: 19580999
[No Abstract] [Full Text] [Related]
16. Long-term experience with imatinib therapy in chronic phase chronic myelogenous leukemia--remarkable activity with room for improvement.
Tefferi A; Kantarjian H
Am J Hematol; 2008 Mar; 83(3):175-7. PubMed ID: 18181199
[No Abstract] [Full Text] [Related]
17. Double Philadelphia-chromosome: a resistance factor on the imatinib mesylate therapy for chronic myeloid leukemia.
Otero L; Ornellas MH; Dobbin J; de Souza Fernandez T
Int J Lab Hematol; 2008 Aug; 30(4):346-8. PubMed ID: 18665834
[No Abstract] [Full Text] [Related]
18. Drug resistance in cancer: principles of emergence and prevention.
Komarova NL; Wodarz D
Proc Natl Acad Sci U S A; 2005 Jul; 102(27):9714-9. PubMed ID: 15980154
[TBL] [Abstract][Full Text] [Related]
19. Detection of BCR-ABL gene mutations in Philadelphia chromosome positive leukemia patients resistant to STI-571 cancer therapy.
Chien JH; Tang JL; Chen RL; Li CC; Lee CP
Leuk Res; 2008 Nov; 32(11):1724-34. PubMed ID: 18603297
[TBL] [Abstract][Full Text] [Related]
20. Resistance and relapse with imatinib in CML: causes and consequences.
Deininger M
J Natl Compr Canc Netw; 2008 Mar; 6 Suppl 2():S11-S21. PubMed ID: 18397677
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]